Psilocybin in Experimental Models of Neurodegeneration
A review of preclinical studies indicates that psilocybin enhances hippocampal plasticity, restores dendritic complexity, reduces inflammation, and aids in fear extinction under neurodegeneration conditions. Observations also suggest possible long-term benefits for anxiety, depression, and cognitive function in individuals with cognitive impairments following psilocybin administration.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not yet assessed
- Mechanism
- Not yet assessed
- Evidence strength
- Not yet assessed
- Outcome
- Not yet assessed
Why it matters
These findings point to psilocybin's potential as a therapeutic intervention in neurodegenerative diseases, suggesting it could affect brain health positively.
What this does not prove
The review does not confirm the clinical efficacy or safety of psilocybin for multiple sclerosis and highlights unresolved issues related to dosing, safety, and transitioning findings to clinical trials.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Systematic review
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-14
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceMechanistic Evaluation of Psilocybin in Neurodegenerative Disorders: Relevance of 5-HT2A Receptors and Downstream Pathways. ↗DOI: 10.2174/0118715273491538261009064612
Supporting passages (6)
study phaseThis review incorporates the most recent data on psilocybin's chemistry, pharmacology, metabolism, and mechanistic actions; it highlights the drug's therapeutic potential across a variety of neurodegenerative diseases and emphasizes the necessity of carefully planned randomized controlled trials to determine clinical efficacy, long-term safety, and its place in multimodal treatment approaches.
study designThis review incorporates the most recent data on psilocybin's chemistry, pharmacology, metabolism, and mechanistic actions; it highlights the drug's therapeutic potential across a variety of neurodegenerative diseases and emphasizes the necessity of carefully planned randomized controlled trials to determine clinical efficacy, long-term safety, and its place in multimodal treatment approaches.
publication date2026-10-14
interventionPsilocybin
findingsPreclinical research studies demonstrate that psilocybin increases hippocampal plasticity, restores dendritic complexity, lowers proinflammatory cytokine levels, and promotes fear extinction in experimental models of stress, ischemic stroke, and neurodegeneration.
limitationsHowever, there are still significant obstacles to overcome, such as optimizing dosing schedules, assessing safety issues such as temporary perceptual abnormalities and cardiovascular consequences, and translating preclinical results into extensive phase -III clinical studies.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.